Related Experiment Videos
Near tetraploid prostate carcinoma. Methodologic and prognostic aspects
G Forsslund1, B Nilsson, A Zetterberg
1Department of Oncology-Pathology, Unit of Tumor Pathology, Karolinska Institute, Stockholm, Sweden.
Cancer
|October 15, 1996
Summary
DNA ploidy analysis in prostate cancer reveals three types: diploid, tetraploid, and aneuploid. Tetraploid tumors can be either slow-growing or aggressive, impacting prognosis and treatment strategies.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- DNA ploidy analysis in prostate carcinoma has been studied for over 20 years.
- Diploid/pseudodiploid tumors generally indicate a favorable prognosis, while aneuploid tumors suggest an unfavorable prognosis.
- Tetraploid (4c) DNA distributions present a diagnostic challenge, potentially indicating either a favorable prognosis (true tetraploid) or an unfavorable prognosis (aneuploid).
Purpose of the Study:
- To investigate the diagnostic challenges posed by 4c tumors in prostate carcinoma.
- To further characterize the prognostic implications of different DNA ploidy types in prostate cancer.
Main Methods:
- A retrospective study involving 334 patients with hormonally treated prostate carcinoma.
- Ploidy classification of cytologic smears using image cytometry.
- Follow-up data collected for up to 30 years or until death.
Main Results:
- Three ploidy types were identified: near-diploid (D), near-tetraploid (T), and highly aneuploid (A).
- Tetraploid region tumors constituted 27% of cases, with 9% classified as T type and 18% as A type.
- A type tumors (54%) progressed rapidly, leading to death within 6 years, while D (37%) and T (9%) type tumors progressed slowly, with deaths occurring 5-30 years post-diagnosis.
Conclusions:
- Prostate carcinoma can be classified into D, T, and A ploidy types via image cytometry.
- Biologically, tumors fall into two groups: low-grade malignant (D or T type) and high-grade malignant (A type).
- This classification aids in distinguishing between slow-progressing and rapidly progressing prostate cancers.